Improved anticancer effect by combining cytotoxic drugs with an inhibitor of prostaglandin synthesis.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D051379:Mice; D009364:Neoplasm Recurrence, Local; D011422:Propionates / Q000627:therapeutic use*; D011448:Prostaglandin Antagonists
D011422:Propionates; D011448:Prostaglandin Antagonists; D005480:Flurbiprofen; D008558:Melphalan; D008727:Methotrexate